GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion–positive rhabdomyosarcoma
暂无分享,去创建一个
Max A. Horlbeck | J. Weissman | A. Sabnis | T. Bivona | W. C. Gustafson | David V Allegakoen | José A García | P. Sahu | Jacqueline Morales | Kristen Kwong | Drew A. Fajardo | Yue Pan | D. Allegakoen | W. Gustafson
[1] Zhiheng Yu,et al. Cryo-EM structures of the human GATOR1-Rag-Ragulator complex reveal a spatial-constraint regulated GAP mechanism. , 2022, Molecular cell.
[2] Wenyu Yang,et al. E3 ligase RNF167 and deubiquitinase STAMBPL1 modulate mTOR and cancer progression. , 2022, Molecular cell.
[3] Luke A. Gilbert,et al. An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer , 2021, Nature Communications.
[4] Peng R. Chen,et al. SAR1B senses leucine levels to regulate mTORC1 signalling , 2021, Nature.
[5] M. Boerries,et al. Negative correlation of single-cell PAX3:FOXO1 expression with tumorigenicity in rhabdomyosarcoma , 2021, Life Science Alliance.
[6] G. Kiss,et al. Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth , 2021, Nature Chemical Biology.
[7] Jun S. Wei,et al. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] F. Barr,et al. A Fusion Transcription Factor–Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target , 2021, Cancer Research.
[9] C. Bellera,et al. Optimal biological dose: a systematic review in cancer phase I clinical trials , 2021, BMC cancer.
[10] A. Gingras,et al. The GATOR–Rag GTPase pathway inhibits mTORC1 activation by lysosome-derived amino acids , 2020, Science.
[11] David C. Smith,et al. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer , 2020, British Journal of Cancer.
[12] Francisco J. Sánchez-Rivera,et al. Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1 , 2020, Nature Cancer.
[13] Kyuho Han,et al. Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities , 2020, bioRxiv.
[14] James R. Anderson,et al. Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Rodeberg,et al. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group , 2019, Cancer medicine.
[16] Emanuel J. V. Gonçalves,et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens , 2019, Nature.
[17] K. Guan,et al. mTOR as a central hub of nutrient signalling and cell growth , 2019, Nature Cell Biology.
[18] Damian Szklarczyk,et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..
[19] F. Barr,et al. Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma , 2018, Molecules.
[20] M. Ferrer,et al. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma , 2018, Science Translational Medicine.
[21] W. Earnshaw,et al. Seh1 targets GATOR2 and Nup153 to mitotic chromosomes , 2018, Journal of Cell Science.
[22] D. Sabatini,et al. Intersubunit Crosstalk in the Rag GTPase Heterodimer Enables mTORC1 to Respond Rapidly to Amino Acid Availability. , 2017, Molecular cell.
[23] M. Ferrer,et al. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. , 2017, Cancer discovery.
[24] Anang A. Shelat,et al. Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors , 2017, Nature.
[25] Phillip G. Montgomery,et al. Defining a Cancer Dependency Map , 2017, Cell.
[26] William A Weiss,et al. A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. , 2017, Cancer cell.
[27] J. Weissman,et al. Combined chemical–genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma , 2016, Proceedings of the National Academy of Sciences.
[28] Youheng Wei,et al. The GATOR2 Component Wdr24 Regulates TORC1 Activity and Lysosome Function , 2016, PLoS genetics.
[29] S. Lowe,et al. Preclinical efficacy of MEK inhibition in Nras-mutant AML. , 2014, Blood.
[30] Wei Wang,et al. Sestrins inhibit mTORC1 kinase activation through the GATOR complex. , 2014, Cell reports.
[31] Max A. Horlbeck,et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation , 2014, Cell.
[32] G. Getz,et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. , 2014, Cancer discovery.
[33] Matthew Meyerson,et al. A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1 , 2013, Science.
[34] L. Staudt,et al. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth , 2013, Oncogene.
[35] M. Hall,et al. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. , 2012, Cell metabolism.
[36] R. Schekman,et al. COPII and the regulation of protein sorting in mammals , 2011, Nature Cell Biology.
[37] Sarat Chandarlapaty,et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.
[38] T. Schwartz,et al. Membrane-coating lattice scaffolds in the nuclear pore and vesicle coats , 2010, Nucleus.
[39] Sang Gyun Kim,et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation , 2008, Proceedings of the National Academy of Sciences.
[40] S. Keir,et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.
[41] C. Proud,et al. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1 , 2008, Oncogene.
[42] Gabriel S. Eichler,et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. , 2007, Cancer research.
[43] L. Helman,et al. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. , 2006, Neoplasia.
[44] Paul Tempst,et al. Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.
[45] J. Biegel,et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma , 1993, Nature Genetics.